Trial · NCT01230593
Chalazion Conservative Treatment Trial
NCT01230593, Not applicable, Completed, McMaster University; results first posted 2018-06-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Chalazion Conservative Treatment Trial. Trials, record NCT01230593. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01230593
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Chalazion Conservative Treatment Trial
- NCT number
- NCT01230593
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 150 participants, actual
- Lead sponsor
- McMaster University
- Conditions
- Chalazion Unspecified Eye, Unspecified Eyelid, Chalazion Left Eye, Unspecified Eyelid, Chalazion Right Eye, Unspecified Eyelid, Chalazion Both Eyes
- Interventions
- Hot Compress plus Tobramycin Drops and Ointment, Hot compress plus Tobramycin/Dexamethasone Drops and Ointment, Hot Compresses
- First posted
- 2010-10-29
- Last updated
- 2018-06-12
- Results first posted
- 2018-06-12
- Limitations and caveats
- Large loss to follow-up - only 70% completed follow-up - was a limitation.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Complete Resolution | 4-6 weeks | Defined as number of patients with chalazion size regression of 100% |
| Secondary | Chalazion Size Difference Post-Treatment | baseline and 4-6 weeks | Change of size of eyelid chalazion in millimeters from baseline to 4-6 weeks post-treatment |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Complete Resolution | 4-6 weeks | Intention to treat population | participants | NUMBER |
| SECONDARY | Chalazion Size Difference Post-Treatment | baseline and 4-6 weeks | Intention to treat population | millimeters | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Complete Resolution | Hot Compress | 13 | participants | ||
| Number of Participants With Complete Resolution | Hot Compress + Tobramycin Drops and Ointment | 12 | participants | ||
| Number of Participants With Complete Resolution | Hot Compress + Tobramycin/Dexamethasone Drops and Ointment | 11 | participants | ||
| Chalazion Size Difference Post-Treatment | Hot Compress | 1.20 | Standard Deviation 3 | millimeters | |
| Chalazion Size Difference Post-Treatment | Hot Compress + Tobramycin Drops and Ointment | 1.69 | Standard Deviation 3 | millimeters | |
| Chalazion Size Difference Post-Treatment | Hot Compress + Tobramycin/Dexamethasone Drops and Ointment | 1.54 | Standard Deviation 3 | millimeters |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Hot Compress | 50 | |
| Overall Study | STARTED | Hot Compress + Tobramycin Drops and Ointment | 50 | |
| Overall Study | STARTED | Hot Compress + Tobramycin/Dexamethasone Drops and Ointment | 50 | |
| Overall Study | COMPLETED | Hot Compress | 35 | |
| Overall Study | COMPLETED | Hot Compress + Tobramycin Drops and Ointment | 32 | |
| Overall Study | COMPLETED | Hot Compress + Tobramycin/Dexamethasone Drops and Ointment | 38 | |
| Overall Study | NOT COMPLETED | Hot Compress | 15 | |
| Overall Study | NOT COMPLETED | Hot Compress + Tobramycin Drops and Ointment | 18 | |
| Overall Study | NOT COMPLETED | Hot Compress + Tobramycin/Dexamethasone Drops and Ointment | 12 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Hot Compress | ||
| Total, all-cause mortality | Hot Compress, Tobrex Drops, Tobrex Ointment | ||
| Total, all-cause mortality | Hot Compress, Tobradex Drops, Tobradex Ointment | ||
| Total, other adverse events | Hot Compress | 0 | 50 |
| Total, other adverse events | Hot Compress, Tobrex Drops, Tobrex Ointment | 0 | 50 |
| Total, other adverse events | Hot Compress, Tobradex Drops, Tobradex Ointment | 0 | 50 |
| Total, serious adverse events | Hot Compress | 0 | 50 |
| Total, serious adverse events | Hot Compress, Tobrex Drops, Tobrex Ointment | 0 | 50 |
| Total, serious adverse events | Hot Compress, Tobradex Drops, Tobradex Ointment | 0 | 50 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29338124 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01230593
GET https://conductscience.org/api/trials/v1/NCT01230593/registered